{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:45:19Z","timestamp":1792507519665,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.autrev.2017.07.022","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T09:31:41Z","timestamp":1501579901000},"page":"1049-1057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":179,"title":["Cancer and autoimmune diseases"],"prefix":"10.1016","volume":"16","author":[{"given":"Eitan","family":"Giat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ehrenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2017.07.022_bb0005","series-title":"Autoimmunity: from bench to bedside","first-page":"683","article-title":"Cancer and autoimmunity","author":"Ehrenfeld","year":"2013"},{"key":"10.1016\/j.autrev.2017.07.022_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1252","article-title":"Cytokines in cancer pathogenesis and cancer therapy","volume":"4","author":"Dranoff","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.autrev.2017.07.022_bb0015","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13075-014-0428-x","article-title":"Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study","volume":"16","author":"Chang","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.022_bb0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0025","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s10067-015-2972-4","article-title":"The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study","volume":"34","author":"Lin","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0030","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00296-014-2982-6","article-title":"No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan","volume":"34","author":"Huang","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2017.07.022_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099388","article-title":"Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting","volume":"9","author":"Andersen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.07.022_bb0040","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/annonc\/mdu365","article-title":"Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study","volume":"25","author":"Fallah","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/annrheumdis-2015-eular.2956","article-title":"FRI0061 cervical dysplasia and cervical cancer in women with rheumatoid arthritis","volume":"74","author":"Wadstr\u00f6m","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0050","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/art.38914","article-title":"2014 ACR\/ARHP annual meeting abstract supplement","volume":"66","author":"Khraishi","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kes350","article-title":"Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population","volume":"52","author":"Mercer","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2017.07.022_bb0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0065","doi-asserted-by":"crossref","first-page":"453012","DOI":"10.1155\/2014\/453012","article-title":"Breast cancer risk in rheumatoid arthritis: an update meta-analysis","volume":"2014","author":"Tian","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.autrev.2017.07.022_bb0070","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.022_bb0075","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.022_bb0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/acr.22997","article-title":"Impact of rheumatoid arthritis on the mortality of elderly patients who develop cancer: a population-based study","volume":"69","author":"Nayak","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.07.022_bb0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12885-016-2444-5","article-title":"Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis","volume":"16","author":"Park","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.autrev.2017.07.022_bb0090","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2014-207155","article-title":"What is the impact of chronic systemic inflammation such as rheumatoid arthritis on mortality following cancer?","volume":"75","author":"Simard","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000957.pub2","article-title":"Methotrexate for treating rheumatoid arthritis","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2017.07.022_bb0100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0105","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2017.07.022_bb0110","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","article-title":"Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"68","author":"Bongartz","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0115","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0120","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0125","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.7314\/APJCP.2014.15.8.3403","article-title":"Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-alpha antagonist therapy: a meta-analysis of randomized control trials","volume":"15","author":"Liu","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.autrev.2017.07.022_bb0130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13075-014-0449-5","article-title":"The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study","volume":"16","author":"Wu","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.022_bb0135","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0140","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.022_bb0145","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0150","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s10067-015-3026-7","article-title":"Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study","volume":"34","author":"Berghen","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2017.07.022_bb0155","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/rheumatology\/kew314","article-title":"The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology biologics register-rheumatoid arthritis","volume":"55","author":"Silva-Fernandez","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.022_bb0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14740338.2016.1238458","article-title":"Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Bonovas","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.autrev.2017.07.022_bb0165","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2017.07.022_bb0175","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0180","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/ard.2008.097527","article-title":"Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment","volume":"68","author":"Simon","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0185","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.38385","article-title":"A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort","volume":"66","author":"Gross","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0190","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/art.38339","article-title":"Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden","volume":"66","author":"Hellgren","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0195","doi-asserted-by":"crossref","first-page":"32063","DOI":"10.1038\/srep32063","article-title":"Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis","volume":"6","author":"Deng","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.022_bb0200","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2017.07.022_bb0205","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.3899\/jrheum.160542","article-title":"Incidence of malignancies in a cohort of psoriatic arthritis patients taking traditional disease modifying Antirheumatic drug and tumor necrosis factor inhibitor therapy: an observational study","volume":"43","author":"Costa","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.semarthrit.2015.10.003","article-title":"Adult onset Still's disease associated with malignancy-cause or coincidence?","volume":"45","author":"Hofheinz","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.022_bb0215","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2013-203305","article-title":"Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis","volume":"73","author":"Liang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0220","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7861\/clinmedicine.14-2-157","article-title":"A retrospective study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year experience","volume":"14","author":"Abrol","year":"2014","journal-title":"Clin Med"},{"key":"10.1016\/j.autrev.2017.07.022_bb0225","doi-asserted-by":"crossref","first-page":"e59868","DOI":"10.1371\/journal.pone.0059868","article-title":"Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort","volume":"8","author":"Gottenberg","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.07.022_bb0230","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semarthrit.2013.03.001","article-title":"Clinical features distinguishing lymphoma development in primary Sjogren's syndrome \u2014 a retrospective cohort study","volume":"43","author":"Risselada","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.022_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116189","article-title":"Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients","volume":"10","author":"Papageorgiou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.07.022_bb0240","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.autrev.2015.03.004","article-title":"Clinical picture, outcome and predictive factors of lymphoma in Sjgren syndrome","volume":"14","author":"Papageorgiou","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.022_bb0245","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00296-014-3051-x","article-title":"Identification of lymphoma predictors in patients with primary Sjogren's syndrome: a systematic literature review and meta-analysis","volume":"35","author":"Nishishinya","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2017.07.022_bb0250","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00432-015-2032-0","article-title":"Systemic lupus erythematosus and malignancies risk","volume":"142","author":"Mao","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0255","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/0961203313520060","article-title":"Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis","volume":"23","author":"Ni","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.07.022_bb0260","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/acr.22751","article-title":"Burden of comorbidity in systemic lupus erythematosus in the UK, 1999\u20132012","volume":"68","author":"Rees","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.07.022_bb0265","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10549-015-3412-5","article-title":"Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population","volume":"151","author":"Khaliq","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.autrev.2017.07.022_bb0270","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1590\/SO100-720320140005052","article-title":"Breast and cervical cancer in patients with systemic lupus erythematosus","volume":"36","author":"Skare","year":"2014","journal-title":"Rev Bras Ginecol Obstet"},{"key":"10.1016\/j.autrev.2017.07.022_bb0275","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2012.12.009","article-title":"Cancer risk in systemic lupus: an updated international multi-centre cohort study","volume":"42","author":"Bernatsky","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2017.07.022_bb0280","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/BOR.0000000000000202","article-title":"Malignancies in systemic lupus erythematosus: a 2015 update","volume":"27","author":"Goobie","year":"2015","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.022_bb0285","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/0961203316664595","article-title":"Breast cancer in systemic lupus","volume":"26","author":"Bernatsky","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.07.022_bb0290","first-page":"6270","article-title":"Thyroid cancer in systemic lupus erythematosus: a meta analysis","volume":"7","author":"Zhang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0295","doi-asserted-by":"crossref","first-page":"R198","DOI":"10.1186\/ar4388","article-title":"Cancer risk in childhood-onset systemic lupus","volume":"15","author":"Bernatsky","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.022_bb0300","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jmii.2014.05.001","article-title":"Comorbidities of pediatric systemic lupus erythematosus: a 6-year nationwide population-based study","volume":"49","author":"Chan","year":"2016","journal-title":"J Microbiol Immunol Infect = Wei mian yu gan ran za zhi"},{"key":"10.1016\/j.autrev.2017.07.022_bb0305","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0961203313490243","article-title":"High-risk variants of cutaneous squamous cell carcinoma in patients with discoid lupus erythematosus: a case series","volume":"22","author":"Flower","year":"2013","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.autrev.2017.07.022_bb0310","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/rheumatology\/kew291","article-title":"Cancer risk in cutaneous lupus erythematosus: a population-based cohort study","volume":"55","author":"Singh","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.022_bb0315","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/0961203315575587","article-title":"What investigations are needed to optimally monitor for malignancies in SLE?","volume":"24","author":"Tessier-Cloutier","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.07.022_bb0320","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/art.39022","article-title":"Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0325","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.022_bb0330","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.autrev.2012.06.003","article-title":"Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature","volume":"12","author":"Colaci","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.022_bb0335","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.autrev.2013.09.006","article-title":"Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian rheumatologic center and a population-based cancer registry and review of the literature","volume":"13","author":"Colaci","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.022_bb0340","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/rheumatology\/kew382","article-title":"Resolution of paraneoplastic PM\/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour","volume":"56","author":"Bruni","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.022_bb0345","doi-asserted-by":"crossref","first-page":"569","DOI":"10.4103\/1947-2714.120788","article-title":"Malignancy and idiopathic inflammatory myopathies","volume":"5","author":"Ungprasert","year":"2013","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.autrev.2017.07.022_bb0350","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Araguas","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.022_bb0355","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2340\/00015555-1550","article-title":"TIF1gamma-overexpressing, highly progressive endometrial carcinoma in a patient with dermato-myositis positive for malignancy-associated anti-p155\/140 autoantibody","volume":"93","author":"Kasuya","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0360","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3899\/jrheum.140566","article-title":"Polymyositis\/dermatomyositis and malignancy risk: a metaanalysis study","volume":"42","author":"Yang","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0365","first-page":"615","article-title":"Incidence and predictive factors for malignancies with dermatomyositis: a cohort from southern China","volume":"32","author":"Chen","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.022_bb0370","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis","volume":"21","author":"Qiang","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.autrev.2017.07.022_bb0375","first-page":"731","article-title":"Low prevalence of malignancy in patients with idiopathic inflammatory myopathies in Jordan","volume":"33","author":"Mustafa","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126016","article-title":"Incidence of cancer in ANCA-associated Vasculitis: a meta-analysis of observational studies","volume":"10","author":"Shang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.07.022_bb0385","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1002\/art.39317","article-title":"Incidence of malignancies in patients with Antineutrophil cytoplasmic antibody-associated vasculitis diagnosed between 1991 and 2013","volume":"67","author":"Rahmattulla","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0390","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/annrheumdis-2013-203465","article-title":"Is cancer associated with polymyalgia rheumatica? A cohort study in the general practice research database","volume":"73","author":"Muller","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0395","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/rheumatology\/keq040","article-title":"Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden","volume":"49","author":"Ji","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2017.07.022_bb0400","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/acr.20062","article-title":"Malignancy risk in patients with giant cell arteritis: a population-based cohort study","volume":"62","author":"Kermani","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.07.022_bb0405","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/art.27429","article-title":"Cancer preceding giant cell arteritis: a case-control study","volume":"62","author":"Kermani","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 6","key":"10.1016\/j.autrev.2017.07.022_bb0410","article-title":"Polymyalgia rheumatica and its association with cancer","author":"Pfeifer","year":"2015","journal-title":"Rheumatology (Sunnyvale)"},{"key":"10.1016\/j.autrev.2017.07.022_bb0415","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MPA.0000000000000053","article-title":"Risk of cancer in autoimmune pancreatitis: a case-control study and review of the literature","volume":"43","author":"Hart","year":"2014","journal-title":"Pancreas"},{"key":"10.1016\/j.autrev.2017.07.022_bb0420","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1210\/jc.2014-1302","article-title":"Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series but not in cytological series: evidence for selection bias","volume":"99","author":"Castagna","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2017.07.022_bb0425","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3109\/s10165-011-0520-x","article-title":"Risk of malignancies in IgG4-related disease","volume":"22","author":"Yamamoto","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0430","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2169\/internalmedicine.53.1342","article-title":"Incidence of malignancies in patients with IgG4-related disease","volume":"53","author":"Hirano","year":"2014","journal-title":"Intern Med"},{"key":"10.1016\/j.autrev.2017.07.022_bb0435","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001275","article-title":"IgG4-related disease: results from a multicenter Spanish registry","volume":"94","author":"Fernandez-Codina","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2017.07.022_bb0440","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3899\/jrheum.150436","article-title":"Association between immunoglobulin G4-related disease and malignancy within 12years after diagnosis: an analysis after longterm followup","volume":"42","author":"Asano","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0445","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3899\/jrheum.140770","article-title":"Risk of overall and site-specific cancers in Behcet disease: a Nationwide population-based study in Taiwan","volume":"42","author":"Wang","year":"2015","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.022_bb0450","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/acr.22941","article-title":"Risk of malignancy among patients with sarcoidosis: a population-based cohort study","volume":"69","author":"Ungprasert","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.07.022_bb0455","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000365877","article-title":"A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution","volume":"133","author":"Peker","year":"2015","journal-title":"Acta Haematol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0460","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1002\/ajh.24333","article-title":"Autoimmune diseases and myelodysplastic syndromes","volume":"91","author":"Komrokji","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0465","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/ejh.12311","article-title":"Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review","volume":"93","author":"Frietsch","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0470","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.4081\/hr.2016.6480","article-title":"Autoimmune syndromes presenting as a paraneoplastic manifestation of myelodysplastic syndromes: clinical features, course, treatment and outcome","volume":"8","author":"Williamson","year":"2016","journal-title":"Hematol Rep"},{"key":"10.1016\/j.autrev.2017.07.022_bb0475","first-page":"197","article-title":"Prevalence and pattern of autoimmune conditions in patients with marginal zone lymphoma: a single institution experience","volume":"79","author":"Dasanu","year":"2015","journal-title":"Conn Med"},{"key":"10.1016\/j.autrev.2017.07.022_bb0480","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/annonc\/mdu144","article-title":"Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype","volume":"25","author":"Fallah","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0485","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.cgh.2013.11.007","article-title":"Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease","volume":"12","author":"Castro","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0490","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.autrev.2017.07.022_bb0495","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00383-013-3321-9","article-title":"Severe autoimmune hemolytic anemia with renal neoplasm","volume":"30","author":"Rhodes","year":"2014","journal-title":"Pediatr Surg Int"},{"key":"10.1016\/j.autrev.2017.07.022_bb0500","first-page":"102","article-title":"Autoimmune hepatitis: an uncommon presentation of thymoma","volume":"11","author":"Mendogni","year":"2016","journal-title":"Tumori"},{"key":"10.1016\/j.autrev.2017.07.022_bb0505","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/B978-0-444-63432-0.00010-4","article-title":"Paraneoplastic and idiopathic autoimmune neurologic disorders: approach to diagnosis and treatment","volume":"133","author":"Pittock","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0510","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrrheum.2014.138","article-title":"Paraneoplastic syndromes in rheumatology","volume":"10","author":"Manger","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0515","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1136\/annrheumdis-2015-207659","article-title":"Autoimmune diseases in adult life after childhood cancer in Scandinavia (ALiCCS)","volume":"75","author":"Holmqvist","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.022_bb0520","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13277-014-2878-9","article-title":"Serum autoantibodies in the early detection of esophageal cancer: a systematic review","volume":"36","author":"Zhang","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0525","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/ijc.28807","article-title":"Systematic review: serum autoantibodies in the early detection of gastric cancer","volume":"136","author":"Werner","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.autrev.2017.07.022_bb0530","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2014.01.007","article-title":"Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer","volume":"346","author":"Chen","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.autrev.2017.07.022_bb0535","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1586\/14737159.2015.1035713","article-title":"Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis","volume":"15","author":"Shi","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.autrev.2017.07.022_bb0540","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/sji.12430","article-title":"Tumour-associated autoantibodies as diagnostic biomarkers for breast cancer: a systematic review and meta-analysis","volume":"83","author":"Xia","year":"2016","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2017.07.022_bb0545","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1158\/0008-5472.CAN-13-2042","article-title":"The Alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant","volume":"74","author":"Wei","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2017.07.022_bb0550","doi-asserted-by":"crossref","first-page":"i262","DOI":"10.1136\/bmj.i262","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden","volume":"352","author":"Raaschou","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2017.07.022_bb0555","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12891-015-0772-2","article-title":"Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study","volume":"16","author":"Buchbinder","year":"2015","journal-title":"BMC Musculoskelet Disord"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217302057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217302057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T22:23:05Z","timestamp":1719354185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217302057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":111,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1568997217302057"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.022","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer and autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}